Technetium (99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mousemonoclonal antibody[1] that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99mradionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of 99mTc-antibody bound cells.[2] Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation[3]
It is approved in European markets for the imaging of infections and inflammations in patients with suspected osteomyelitis[4][5] but has not secured FDA approval for use in American markets.[6] In addition to approved uses, Leukoscan is currently being investigated for other diagnostic purposes like the detection of soft tissue infections, malignant external otitis and prosthetic joint infection.[7][8][9] However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company Immunomedics was discontinued in 2018.[10]
^Gratz S, Reize P, Kemke B, Kampen WU, Luster M, Höffken H (December 2016). "Targeting osteomyelitis with complete [99mTc]besilesomab and fragmented [99mTc]sulesomab antibodies: kinetic evaluations". The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 60 (4): 413–23. PMID25325395.
^Vicente AG, Almoguera M, Alonso JC, Heffernan AJ, Gomez A, Contreras PI, Martin-Comin J (December 2004). "Diagnosis of orthopedic infection in clinical practice using Tc-99m sulesomab (antigranulocyte monoclonal antibody fragment Fab'2)". Clinical Nuclear Medicine. 29 (12): 781–5. doi:10.1097/00003072-200412000-00001. PMID15545877. S2CID46580717.
^Galletti F, Cammaroto G, Galletti B, Quartuccio N, Di Mauro F, Baldari S (June 2015). "Technetium-99m (99mTc)-labelled sulesomab in the management of malignant external otitis: is there any role?". European Archives of Oto-Rhino-Laryngology. 272 (6): 1377–82. doi:10.1007/s00405-014-2938-1. PMID24534898. S2CID25194736.
